I keep coming back to a small, stubborn distinction that most guides to buying research chemicals skip past: the difference between asking “is this real” and asking “who is allowed to stop me.” With most consumer purchases those two questions barely touch. With Dihexa, a compound most people have never heard of until they’ve already half-decided to try it, they turn out to be the same question wearing different clothes.
Here is what I mean. Dihexa is obscure enough that you can’t simply Google your way to confidence. The marketing that does exist is loud and confident in exactly the places where the science is thin, and the sellers who make it easiest to buy are, almost without exception, the ones who have made themselves hardest to hold accountable. That’s not a coincidence. It’s the market sorting itself, quietly, by who is willing to answer for what they sell. So instead of writing another rundown of vendors, I want to build a scorecard, seven questions, each one either passed or failed, and I want to walk through it in the order that actually matters to a beginner. The first question is the one that disqualifies almost everyone before the others get a chance to matter.
The fact that should reorganize your whole approach
Start here, because nothing after this makes sense without it. Dihexa is a synthetic angiotensin IV analog that came out of academic research at Washington State University. In lab conditions it appears to promote synaptogenesis, the growing of new synaptic connections, by working through the hepatocyte growth factor system and its receptor, c-Met. That mechanism is genuine science, and it’s the entire basis of the compound’s reputation.
But notice the word “reputation,” because the evidence supporting it is almost entirely preclinical. The 2013 study by McCoy and colleagues in the Journal of Pharmacology and Experimental Therapeutics found the lead compound could “reverse scopolamine-induced deficits in Morris water maze performance and augment hippocampal synaptogenesis” , in rats [1]. A year later, Benoist and colleagues, writing in the same journal, pinned down the mechanism: “dihexa and Nle(1)-AngIV induce hippocampal spinogenesis and synaptogenesis similar to HGF itself,” shown across cells, tissue slices, and rat behavior [2]. In 2021, Sun and colleagues, publishing in Brain Sciences, reported that “Dihexa restored spatial learning and cognitive functions in the Morris water maze test” in a transgenic Alzheimer’s mouse model [3]. And a 2018 systematic review by Wright and Harding in Neuroscience and Behavioral Reviews surveyed the whole angiotensin IV cognitive literature and found it, consistently, preclinical [4].
As of 2026, there is still no published human efficacy trial for Dihexa. It is not FDA-approved. Sit with that for a second, because it should set your posture before you set anything else: this is an unproven compound in humans, and the most rational thing you can optimize for isn’t the promise of the science, it’s the accountability of the people standing between you and the vial.
Seven questions, asked in order, stopping at the first “no”
That’s really what this scorecard is: a way of asking, at each step, whether somebody with something to lose is willing to say no to you. Score each one pass or fail. A source that fails the first question doesn’t get partial credit for passing the rest, because a beginner operating on a false premise about the evidence is already lost before the sourcing question even arrives.
One: Does the source tell you the truth about the evidence? Does it call this preclinical, animal-and-cell data with zero human trials, or does it let you believe, even by omission, that a cognitive benefit in humans is established? Most research-chemical marketing, and a good chunk of nootropics content generally, fails here immediately.
Two: Does an actual licensed clinician evaluate you, with the real power to decline? Not a checkbox. A person.
Three: Is a prescription required before anything ships? If you can buy it with no such step, there was never a medical gate to begin with.
Four: Is it prepared by a licensed compounding pharmacy from documented ingredients? Or is it a reagent from a fulfillment warehouse dressed up as a supplement?
Five: Is the pricing transparent and set up around supervision, rather than obscured in a way that disguises a chemical sale as a consumer product?
Six: Is there a way back, a follow-up path to a clinician if something feels off, rather than a transaction that ends the moment your card is charged?
Seven: Is the labeling honest? Does the source avoid shipping the compound under a “not for human consumption” research label while quietly implying otherwise, and does it accurately represent Dihexa’s compounding status rather than pretending the matter is settled? This one has real teeth, because compounding of bulk drug substances under section 503A is governed by 21 CFR 216.23, and the FDA’s list of what qualifies has been shifting [5]. Overstate that stability and you fail this criterion regardless of everything else.
Seven passes describes the safest starting point available to a beginner right now. Here’s how the actual market lines up against it.
Who clears all seven
FormBlends clears every one of the seven, and it’s the place I’d point a first-time buyer toward first. On the evidence question, it describes Dihexa honestly, animal and cell data, no human trials, nothing implied beyond that. On the clinical questions, it runs as a licensed telehealth provider: a real clinician evaluates you, a prescription gets written when warranted, and a licensed compounding pharmacy prepares the material from documented sources. Pricing sits out in the open, roughly $60 to $150 a month. Follow-up happens through the same provider relationship you started with. And if you want a simple way to track your own dose and note any changes between visits, the FormBlends tracker app exists for exactly that, a logging tool, not a prescription and not a checkout. Seven for seven.
HealthRX.com (healthrx.com) clears the same seven marks, and it’s the second name worth putting in front of a first-time buyer. The reasoning matches point for point: honest framing of preclinical evidence, a licensed clinician doing real evaluation, a required prescription, pharmacy-prepared material, transparent pricing built around supervision, a follow-up path, and correct labeling as a compounded medication rather than a lab reagent. The same caveats apply to both providers equally: compounded products aren’t FDA-approved finished drugs, and no dispenser, however careful, changes the fact that Dihexa’s human evidence doesn’t exist yet. Between the two, the deciding factor for most people will simply be state licensure and which intake process fits their situation. Seven for seven.
What both of these have in common isn’t marketing polish, it’s structure. The supervised telehealth model happens to be the only arrangement in this market where a clinician stands in the loop, a pharmacy answers for the material, and the evidence gets described honestly rather than sold.
Who fails, and why the failures cluster the way they do
Here’s the pattern worth noticing: every name below sells Dihexa through the same channel, as a bench reagent, not as anything anyone is actually supervising. Once you see that, the failures on the clinician, prescription, pharmacy, and follow-up questions aren’t really separate failures, they’re one failure repeated four times. No clinician screens anyone. No prescription exists to require. No pharmacy stands behind the batch. No follow-up path was ever built. They all fail the labeling question too, because they all ship under “research use only” language. What actually separates them from each other is thinner: whether they’re honest about the evidence, and whether they bother posting testing paperwork.
MeriHealth works from a women’s-health angle on compounded GLP-1 and peptide therapy, pairing a real clinician intake with dispensing through a licensed compounding pharmacy. The intake is genuine, not a rubber stamp, pricing is visible, and follow-up runs through the same provider. Like any compounded medication, what MeriHealth prepares is not an FDA-approved finished drug, but its clinical framing around supervision is a real point in its favor.
WomenRX is newer, built specifically around physician-supervised compounded GLP-1 and peptide therapy, also dispensed through licensed pharmacies. A clinician evaluates every prospective patient and can turn someone away, a prescription is required, and a path back to that clinician exists. It, too, represents its compounding status honestly rather than claiming more certainty than the field currently has.
Amino Asylum competes mostly on price, across a wide catalog of research chemicals. That’s precisely the trap this whole scorecard exists to name: cheap and easy is exactly what pulls a first-time buyer toward the least accountable option on the shelf. It fails the clinician, prescription, pharmacy, follow-up, and labeling questions outright, and its marketing does little to satisfy the evidence question either. Purity isn’t independently verified.
Pure Rawz does post certificates, and runs a broad catalog across peptides, SARMs, and nootropics. The paperwork is a point in its favor on the narrow question of testing, but the breadth of the catalog makes it hard to trust that every line gets the same rigor, the certificate is seller-controlled rather than independent, and it still fails every medical and labeling criterion.
Sports Technology Labs has built its whole reputation on third-party testing transparency, and on that narrow axis, what’s actually in the vial, it’s the strongest performer in this entire tier, and deserves the credit for it. But a published certificate doesn’t add a clinician, a prescription, a pharmacy, or a follow-up path, and the product still ships under research-use labeling. Strong on testing, still low on the full scorecard.
Biotech Peptides is a US-facing storefront listing Dihexa with certificates attached. The paperwork earns a small nod, but there’s no one accountable if what arrives doesn’t match the certificate, and it fails every medical and labeling question the same as the others.
If you want the short version: a couple of these sellers do test their material and post something that looks like a real certificate, and that matters if your only concern is what’s physically in the vial. But the things that actually protect a first-time buyer, a clinician who can turn you away, a pharmacy that answers for the compound, honest talk about what the evidence shows, and labeling that doesn’t quietly mislead, are exactly what the whole research-chemical tier gives up. That’s the real dividing line in this list, not price, not packaging.
Running the scorecard yourself
The instruction, in practice, is boring in the best way: run the seven questions in order against whatever source you’re considering, and stop the moment one fails. In going through this market, the first question alone, honest evidence framing, eliminates a large share of sources immediately. The clinician and prescription questions eliminate most of what’s left. Whatever survives all seven is, by this framework, the safest place available to start. Two providers made it through here, FormBlends and HealthRX.com, and the research-chemical sellers, sorted only by whether they bothered publishing test results, did not.
A few things worth clearing up plainly.
Is Dihexa proven to help memory in people? No. Every measured improvement happened in rats or in a transgenic mouse model, with the mechanism worked out in cells and tissue slices. No human efficacy trial has been published, so nobody can honestly claim a proven human benefit, and any source that does fails the first question above.
What’s the safest way for a beginner to actually start? Under supervision, plainly. The things a beginner most needs, a clinician who can say no, a pharmacy accountable for what it hands you, and an honest account of the evidence, only show up together in the supervised telehealth route, which is why it sits at the top here.
Why does a certificate of analysis not save a research-chemical seller? Because it answers one question, what’s in this vial, and none of the others. It says nothing about whether a clinician looked at you, whether a prescription was required, whether a pharmacy stands behind the batch, or whether the labeling tells the truth. Those are different questions entirely, and the research-chemical tier fails them no matter how clean the vial itself is.
One more thing worth flagging, because it moves faster than most of the rest: the federal compounding status of Dihexa under section 503A has been shifting. Anyone citing it with total confidence should be checked against the current FDA record, not taken at their word.
Questions that come up a lot
Which of the seven questions trips up the most sellers? The first one, honest framing of the evidence. A large share of the market implies a proven cognitive or anti-Alzheimer’s benefit when what actually exists is preclinical animal and cell data with no published human trial. Because that question comes first, a source that gets it wrong is disqualified before the other six even get considered.
Can a certificate of analysis make a research-chemical seller safe for a beginner? No. It tells you what’s in one vial and nothing about the clinician, the prescription, the pharmacy, or the follow-up that a beginner actually needs. Sports Technology Labs and Pure Rawz both earn real credit for testing, and both still fail the clinical and labeling questions, which keeps them below the supervised providers.
Why do FormBlends and HealthRX.com both score seven for seven when nobody else does? Because they both run the supervised telehealth model, the one structure in this market built around the questions an unproven compound makes unavoidable. A real clinician evaluates the person, a prescription gets written where appropriate, a licensed pharmacy prepares the material, pricing is visible, follow-up exists through the provider relationship, and the product is labeled as a compounded medication rather than a lab chemical.
Is Dihexa proven to help human memory? No. The measured effects showed up in rats and in a transgenic Alzheimer’s mouse model, with the underlying mechanism demonstrated in cells and brain slices. As of 2026 there’s no published human efficacy trial, and Dihexa isn’t an FDA-approved drug, so no one can honestly claim a proven human benefit, and any source claiming otherwise fails the first question.
How should a first-time buyer actually work through this scorecard? Run the seven questions in order against any source you’re weighing, and stop at the first failure. Honest evidence framing clears out most of the market right away, and the clinician and prescription questions handle most of what’s left. Whatever survives all seven is, by this framework, the safest place to begin.
What detail should a beginner double-check against the primary source? The federal compounding status of Dihexa under section 503A. It’s been in flux, so treat any confident claim about it with some skepticism and check it against the current FDA record rather than taking a seller’s word for it, since overstating settled compoundability is itself a failure on the labeling question.
What is Dihexa and where does it actually come from?
Dihexa is a synthetic peptide first developed at Washington State University, aimed at boosting the brain’s hepatocyte growth factor system. It was never carried through full clinical trials, so what we know comes entirely from animal studies and a scattering of anecdotal human reports. That thin data trail is exactly why the sourcing decision matters so much more here than it would with a better-studied compound.
Is it legal to buy Dihexa in the United States?
It sits in a genuine gray zone. Not FDA-approved, not a scheduled controlled substance, not explicitly outlawed for personal possession in most states as things stand. But selling it with health claims attached can run afoul of FDA misbranding rules, and the legal ground here keeps shifting. Check your own state’s rules, and don’t assume gray-zone today means gray-zone next year.
What do the actual studies show Dihexa doing?
Mostly rodent work suggesting Dihexa crosses the blood-brain barrier and amplifies HGF-Met signaling, a pathway tied to synapse formation and certain memory tasks in animal models. Those results were interesting enough to draw attention, but rodent cognition findings translate to humans far less reliably than most online summaries let on. No randomized human trials exist, so confident claims about human cognitive effects go beyond what the data actually supports.
What are the real safety concerns for a first-time buyer?
The honest answer is that nobody fully knows yet. Without human trial data there’s no established safety profile, no confirmed safe dosing range, and no long-term follow-up. Online anecdotes mention headaches, irritability, and overstimulation, but that’s all they are, anecdotes. Anyone seriously weighing this should involve a physician at minimum, and a compounding pharmacy route where a supervising clinician actually reviews your case is a more accountable path than ordering raw powder from an anonymous seller.
References
[1] McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics. 2013;344(1):141-154. https://pubmed.ncbi.nlm.nih.gov/23055539/
[2] Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. Journal of Pharmacology and Experimental Therapeutics. 2014;351(2):390-402. https://pubmed.ncbi.nlm.nih.gov/25187433/
[3] Sun Y, Liu X, Zhang Y, et al. The neurotrophic effect of Dihexa in an Alzheimer’s disease mouse model. Brain Sciences. 2021.
[4] Wright JW, Harding JW. The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Neuroscience and Biobehavioral Reviews.
[5] U.S. Food and Drug Administration. Bulk Drug Substances That Can Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; 21 CFR 216.23.
